Compare Stocks: TCRX, ONCY, RNTX, and IBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBIO iBio	$0.82 +5.7%	$1.01	$0.69 ▼ $3.82	$53.00M	1.47	1.07 million shs	361,507 shs
ONCY Oncolytics Biotech	$0.41 +7.8%	$0.61	$0.37 ▼ $1.30	$53.97M	1.26	1.26 million shs	1.49 million shs
RNTX Rein Therapeutics	$0.61 +2.7%	$0.72	$0.54 ▼ $2.10	$52.28M	1.47	432,406 shs	307,123 shs
TCRX TScan Therapeutics	$0.19 +0.2%	$0.28	$0.17 ▼ $1.47	$12.58M	1.21	719,323 shs	292,699 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBIO iBio	-1.89%	-5.28%	-10.45%	-46.94%	-39.53%
ONCY Oncolytics Biotech	-6.35%	-2.10%	-31.45%	-53.65%	-64.32%
RNTX Rein Therapeutics	-4.98%	-11.61%	-25.69%	-26.71%	-61.69%
TCRX TScan Therapeutics	+1.98%	-2.01%	-22.18%	-76.04%	-83.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBIO iBio	$0.82 +5.7%	$1.01	$0.69 ▼ $3.82	$53.00M	1.47	1.07 million shs	361,507 shs
ONCY Oncolytics Biotech	$0.41 +7.8%	$0.61	$0.37 ▼ $1.30	$53.97M	1.26	1.26 million shs	1.49 million shs
RNTX Rein Therapeutics	$0.61 +2.7%	$0.72	$0.54 ▼ $2.10	$52.28M	1.47	432,406 shs	307,123 shs
TCRX TScan Therapeutics	$0.19 +0.2%	$0.28	$0.17 ▼ $1.47	$12.58M	1.21	719,323 shs	292,699 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBIO iBio	-1.89%	-5.28%	-10.45%	-46.94%	-39.53%
ONCY Oncolytics Biotech	-6.35%	-2.10%	-31.45%	-53.65%	-64.32%
RNTX Rein Therapeutics	-4.98%	-11.61%	-25.69%	-26.71%	-61.69%
TCRX TScan Therapeutics	+1.98%	-2.01%	-22.18%	-76.04%	-83.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IBIO iBio	3.00	Buy	$6.00	627.98% Upside
ONCY Oncolytics Biotech	2.00	Hold	$5.00	1,114.77% Upside
RNTX Rein Therapeutics	2.25	Hold	$6.00	890.10% Upside
TCRX TScan Therapeutics	2.14	Hold	$2.67	1,336.78% Upside

Current Analyst Ratings Breakdown

Latest TCRX, ONCY, RNTX, and IBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/10/2026	ONCY Oncolytics Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/26/2026	ONCY Oncolytics Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/9/2026	ONCY Oncolytics Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/21/2026	IBIO iBio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/17/2026	IBIO iBio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$7.00
9/17/2026	IBIO iBio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$7.00
9/8/2026	TCRX TScan Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Neutral	$1.00
9/2/2026	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Neutral	$1.00
9/2/2026	TCRX TScan Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
8/21/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 11/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IBIO iBio	$100K	530.04	N/A	N/A	$1.54 per share	0.54
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	($0.04) per share	N/A
RNTX Rein Therapeutics	N/A	N/A	$0.06 per share	10.86	($1.07) per share	N/A
TCRX TScan Therapeutics	$10.32M	1.22	N/A	N/A	$2.16 per share	0.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IBIO iBio	-$33.04M	-$0.34	N/A	N/A	N/A	N/A	-40.66%	-35.78%	N/A
ONCY Oncolytics Biotech	-$28.76M	-$0.34	N/A	N/A	N/A	N/A	N/A	-442.99%	11/11/2026 (Estimated)
RNTX Rein Therapeutics	-$49.87M	-$1.72	N/A	N/A	N/A	N/A	N/A	-63.69%	N/A
TCRX TScan Therapeutics	-$129.77M	-$0.91	N/A	N/A	N/A	-1,655.35%	-108.72%	-54.47%	11/11/2026 (Estimated)

Latest TCRX, ONCY, RNTX, and IBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ONCY Oncolytics Biotech	-$0.0539	N/A	N/A	N/A	N/A	N/A
11/11/2026	Q3 2026	TCRX TScan Therapeutics	-$0.1871	N/A	N/A	N/A	$0.46 million	N/A
11/10/2026	Q1 2027	IBIO iBio	-$0.07	-$0.05	+$0.02	-$0.05	$0.03 million	$1.08 million
8/28/2026	Q4 2026	IBIO iBio	-$0.0655	-$0.04	+$0.0255	-$0.0680	$0.08 million	N/A
8/14/2026	Q2 2026	RNTX Rein Therapeutics	-$0.27	-$0.10	+$0.17	-$0.10	N/A	N/A
8/12/2026	Q2 2026	ONCY Oncolytics Biotech	-$0.0538	-$0.08	-$0.0262	-$0.08	N/A	N/A
8/12/2026	Q2 2026	TCRX TScan Therapeutics	-$0.2534	-$0.23	+$0.0234	-$0.23	$1.88 million	$1.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IBIO iBio	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IBIO iBio	N/A	7.85	7.85
ONCY Oncolytics Biotech	N/A	1.35	1.35
RNTX Rein Therapeutics	N/A	4.27	4.27
TCRX TScan Therapeutics	0.31	3.37	3.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IBIO iBio	7.90%
ONCY Oncolytics Biotech	6.82%
RNTX Rein Therapeutics	90.89%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
IBIO iBio	1.55%
ONCY Oncolytics Biotech	4.68%
RNTX Rein Therapeutics	1.50%
TCRX TScan Therapeutics	13.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IBIO iBio	23	64.31 million	63.31 million	N/A
ONCY Oncolytics Biotech	29	131.12 million	124.99 million	Not Optionable
RNTX Rein Therapeutics	10	86.27 million	84.97 million	N/A
TCRX TScan Therapeutics	142	67.78 million	58.40 million	Not Optionable

TCRX, ONCY, RNTX, and IBIO Headlines

Recent News About These Companies

TScan Therapeutics (TCRX) Expected to Post Quarterly Earnings on Wednesday

November 10 at 2:43 AM | americanbankingnews.com

TScan Therapeutics Announces Resignations of Nicholson and Gruia, Board Committee Restructuring

October 18, 2026 | kalkinemedia.comK

TScan Therapeutics Announces Board and Governance Changes

October 16, 2026 | tipranks.com

TScan Therapeutics consensus price target decreased by 55.56% to $2.72

September 16, 2026 | msn.com

Wedbush downgrades TScan Therapeutics (TCRX) to neutral from outperform

September 3, 2026 | msn.com

TScan Therapeutics Reorganizes To Focus On Solid Tumor Program; To Cut 75% Jobs; Stock Tumbles 11%

September 2, 2026 | rttnews.com

TScan Therapeutics cuts workforce by 75% and shifts focus to solid tumor program

September 2, 2026 | msn.com

TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction

September 2, 2026 | benzinga.com

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

September 2, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Immix Biopharma (IMMX), TScan Therapeutics (TCRX) and enGene Holdings (ENGN)

August 13, 2026 | theglobeandmail.com

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

August 12, 2026 | zacks.com

TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results

August 12, 2026 | quiverquant.comQ

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | globenewswire.com

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

July 29, 2026 | globenewswire.com

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

June 24, 2026 | globenewswire.com

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic ...

June 23, 2026 | markets.businessinsider.com

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

June 22, 2026 | globenewswire.com

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

June 3, 2026 | businesswire.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss

June 2, 2026 | insidermonkey.com

TScan Therapeutics Expands Authorized Shares After Stockholder Vote

May 22, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX, ONCY, RNTX, and IBIO Company Descriptions

iBio NASDAQ:IBIO

$0.82 +0.04 (+5.67%)

Closing price 04:00 PM Eastern

Extended Trading

$0.81 -0.01 (-1.72%)

As of 06:23 PM Eastern

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Oncolytics Biotech NASDAQ:ONCY

$0.41 +0.03 (+7.81%)

Closing price 04:00 PM Eastern

Extended Trading

$0.41 +0.00 (+0.58%)

As of 07:10 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Rein Therapeutics NASDAQ:RNTX

$0.61 +0.02 (+2.71%)

Closing price 04:00 PM Eastern

Extended Trading

$0.61 +0.00 (+0.33%)

As of 04:10 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

TScan Therapeutics NASDAQ:TCRX

$0.19 +0.00 (+0.22%)

Closing price 04:00 PM Eastern

Extended Trading

$0.18 0.00 (-0.32%)

As of 05:24 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TCRX, ONCY, RNTX, and IBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TCRX, ONCY, RNTX, and IBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TCRX, ONCY, RNTX, and IBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX, ONCY, RNTX, and IBIO Company Descriptions

iBio NASDAQ:IBIO

Oncolytics Biotech NASDAQ:ONCY

Rein Therapeutics NASDAQ:RNTX

TScan Therapeutics NASDAQ:TCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TCRX, ONCY, RNTX, and IBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TCRX, ONCY, RNTX, and IBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TCRX, ONCY, RNTX, and IBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX, ONCY, RNTX, and IBIO Company Descriptions

iBio NASDAQ:IBIO

Oncolytics Biotech NASDAQ:ONCY

Rein Therapeutics NASDAQ:RNTX

TScan Therapeutics NASDAQ:TCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools